Nov 30, 2016 5:28 pm EST Heat Biologics Presents Topline HS-410 Phase 2 Bladder Cancer Results at the Society of Urological Oncology Annual Meeting
Nov 17, 2016 7:00 am EST Heat Biologics to Present Topline HS-110/Nivolumab Combination Phase Ib Lung Cancer Results at the International Society for the Study of Lung Cancer Annual Meeting
Nov 16, 2016 7:00 am EST Heat Biologics to Present Topline HS-410 Phase II Bladder Cancer Results at the Society of Urological Oncology Annual Meeting
Nov 14, 2016 7:00 am EST Heat Biologics Presents ComPACT Preclinical Data at the Society for Immunotherapy of Cancer Annual Meeting
Nov 10, 2016 4:47 pm EST Heat Biologics Provides Corporate Update and Reports Third Quarter 2016 Financial Results
Nov 07, 2016 7:00 am EST Heat Biologics to Present at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 17, 2016 7:30 am EDT Heat Biologics to Present at Two Upcoming Investor Conferences and Panel Discussion
Oct 13, 2016 7:00 am EDT Heat Biologics Remains on Track to Achieve Multiple Topline Data Readouts this Quarter
Oct 11, 2016 7:30 am EDT Heat Biologics Selects Adaptive Biotechnologies to Discover Potential Clinical Biomarkers to Advance Novel Immunotherapies